02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
02 Feb - 
Adaptimmune and GSK Expand Strategic Immunotherapy Coll..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD


-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Result of Elections of Scrip Dividend Scheme

25/10/2016 14:32:36
The Weir Group PLC Scrip Dividend Further to the announcement made on 29 September 2016, The Weir Group PLC ("the Company") confirms that shareholders repr..

Rathbone Brothers Plc : Holding(s) in Company

25/10/2016 11:34:22
For filings with the FSA include the annex   For filings with issuer..

Rathbone Brothers Plc : Director/PDMR Shareholding

25/10/2016 10:49:53
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
The Scottish Salmon Company: Board of Directors
Companies shifting more R&D spending away from physical products to software and services: 2016 Global Innovation 1000 Study
DBV Technologies: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
CrossAmerica Partners LP: Declares 10th Consecutive Quarterly Distribution Increase
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

Related stock quotes

Glaxosmithkline PLC ORD .. 1,646.24 0.3% Stock price increasing
GlaxoSmithKline PLC 40.39 -0.7% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 October 2016 20:01:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20161024.1 - EUROWEB6 - 2016-10-25 21:01:31 - 2016-10-25 20:01:31 - 1000 - Website: OKAY